Bladder Cancer

Dr. Charles Peyton discusses the growing number of bladder cancer therapies and emphasizes the importance of personalized care and patient education.

Stage 1 urothelial carcinoma is highly treatable; learn about diagnosis, treatment options and how to reduce recurrence risk through ongoing monitoring.

NCCN guidelines now include plus BCG for certain BCG-unresponsive bladder cancer patients, expanding treatment options.

Though I don’t understand why I’m suffering, I try to hold onto my faith and believe that God is somehow still working in me.

Dr. Matthew Galsky discusses the background of the KEYNOTE-B15 study, the key results and what these findings could mean for patients.

Phase 2 interim data show NDV-01 produced high response rates and encouraging safety in patients with non–muscle-invasive bladder cancer.

The FDA has received a new application for Anktiva plus BCG to treat BCG-unresponsive non–muscle invasive bladder cancer with papillary tumors.

Phase 2 INDIBLADE data support Yervoy and Opdivo before bladder-sparing chemoradiotherapy.

Disitamab vedotin demonstrated responses in previously treated HER2-expressing advanced urothelial carcinoma, with activity across HER2 expression levels.

Padcev plus Keytruda before and after surgery helped more bladder cancer patients live longer and remain cancer-free than standard chemotherapy.

Oncologists highlight key 2026 ASCO GU studies in bladder, prostate, kidney and testicular cancers that could reshape treatment and personalize care.

Through personal stories and a research study on group drumming, Chester Freeman explores the reality of "chemo brain" and the power of finding rhythm in recovery.

Padcev plus Keytruda demonstrated clinically meaningful and statistically significant improvements in event-free survival and overall survival for MIBC.

This guide features information from diagnosis to treatment of adenocarcinoma of the bladder.

TARA-002 may offer meaningful benefits for patients with non-muscle invasive bladder cancer, including those who have limited treatment options.

From diagnosis to treatment, here is what patients need to know about squamous cell carcinoma of the bladder.

The FDA granted fast track designation to AVZO-103 for the treatment of patients with previously treated locally advanced or metastatic urothelial cancer.

Keytruda and Padcev improve event-free and overall survival for adults with muscle invasive bladder cancer who cannot receive cisplatin after surgery.

Leading oncology experts share emerging research and developments shaping the year ahead, from precision medicine to innovative cancer therapies.

Trial data showed a 62% complete response rate at 6 months with detalimogene coraplasmid among patients with high-risk, BCG-unresponsive bladder cancer.

Dr. Joshua Sabari, Dr. Petros Grivas, and Dr. Chandler Park discuss new developments in perioperative therapy for muscle-invasive bladder cancer.

Dr. Minetta Liu explains how Signatera detects tumor DNA after bladder surgery, guiding treatment and identifying patients who need immunotherapy.

Participating in the SUNRiSE-1 trial taught Bill, a USC Norris patient, the value of education, teamwork, and persistence for patients with bladder cancer.

Bill, a USC Norris patient, joined the SUNRiSE-1 trial for Inlexzo, avoiding bladder removal and reaching full remission from BCG-unresponsive bladder cancer.

Fran Curtis is a survivor of breast, appendix and skin cancer, but said bladder cancer was the toughest.